Harbour BioMed reels in $75M as proprietary pipeline hits clinic

Harbour BioMed has raised $75 million to continue moving multiple candidates through the clinic. The round, which Harbour described as a “series B+,” comes shortly after the antibody specialist took its first internally originated candidate into the clinic outside of greater China.

Harbour BioMed reels in $75M as proprietary pipeline hits clinic
Harbour BioMed has raised $75 million to continue moving multiple candidates through the clinic. The round, which Harbour described as a “series B+,” comes shortly after the antibody specialist took its first internally originated candidate into the clinic outside of greater China.